Home > Journals > Minerva Ginecologica > Past Issues > Articles online first > Minerva Ginecologica 2020 Jul 17

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

 

Minerva Ginecologica 2020 Jul 17

DOI: 10.23736/S0026-4784.20.04601-8

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

The role of the sentinel lymph node in vulvar cancer

Andrea GIANNINI, Ottavia D'ORIA, Giusi SANTANGELO , Carlo M. ALLEGRINI, Giuseppe CARUSO, Anna DI PINTO, Giorgia PERNIOLA, Innocenza PALAIA, Marco MONTI, Ludovico MUZII, Pierluigi BENEDETTI PANICI, Violante DI DONATO

Department of Maternal and Child Health and Urologic Sciences, Sapienza University, Umberto I Hospital, Rome, Italy


PDF


OBJECTIVE: The aim of this study is to update clinical practice applications and technical procedures regarding sentinel lymph node (SLN) biopsy in vulvar cancer considering European experts’ opinions from this field.
EVIDENCE ACQUISITION: Systematic data search performed using PubMed/MEDLINE database up to May 20, 2020. Focus was only for English language publications of original studies on SLN biopsy in vulvar cancer.
EVIDENCE SYNTHESIS: Given the basis of published evidence and the consensus of European experts, this study provides an updated overview on clinical applications and technical procedures of SLN biopsy in vulvar cancer.
CONCLUSIONS: In early-stage vulvar cancer patients with a negative sentinel node, the groin recurrence rate is low, survival is excellent, and treatment-related morbidity is minimal. We advise that sentinel node dissection, performed by a quality-controlled multidisciplinary team, should be part of the standard treatment in selected patients with early-stage vulvar cancer.


KEY WORDS: Vulvar cancer; Sentinel lymph node; Prognosis

top of page